# Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

> **NCT01526733** · PHASE4 · COMPLETED · sponsor: **Halozyme Therapeutics** · enrollment: 25 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Sham Injection
- **DRUG:** Recombinant human hyaluronidase PH20
- **DRUG:** Insulin aspart
- **DRUG:** Insulin lispro

## Key facts

- **NCT ID:** NCT01526733
- **Lead sponsor:** Halozyme Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2012-08
- **Final completion:** 2013-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01526733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01526733, "Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01526733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*